Increasingly higher dosages will result in higher toxicity, resembling [[vitamin A toxicity]]. The following are adverse drug reactions from Roche's UK product information for Roaccutane as of October 2010:<ref name="urlIsotretinoin 20mg capsules - Summary of Product Characteristics (SPC) - (eMC)">{{cite web | url = http://www.medicines.org.uk/emc/medicine/15655/spc | title = Isotretinoin 20 mg capsules,  Summary of Product Characteristics | format = | work = electronic Medicines Compendium (eMC) | publisher = Datapharm Communications Ltd }}</ref>

 


 
{| class="wikitable"

 
! 

 
Type of disorders

 
! 

 
Very common  (≥ 1/10) 

 
! 

 
Common (≥ 1/100, < 1/10) 

 
! 

 
Rare (≥ 1/10 000,< 1/1000) 

 
! 

 
Very rare (≤ 1/10 000)

 
|-

 
| '''Infections'''

 
|

 
|

 
|

 
|

 
* Gram positive (mucocutaneous)

 
bacterial infection

 
|-

 
| '''Blood and [[lymphatic system]]'''

 
|

 
* [[Anemia]]

 
* Increased red blood cell sedimentation rate

 
* [[Thrombocytopenia]]

 
* [[Thrombocytosis]]

 
|

 
* [[Neutropenia]]

 
|

 
|

 
* Lymphadenopathy

 
|-

 
| '''[[Immune system]]'''

 
|

 
|

 
|

 
* Allergic skin reaction

 
* [[Anaphylactic]] reactions

 
* Hypersensitivity

 
|

 
|-

 
| '''[[Metabolism]]'''

 
|

 
|

 
|

 
|

 
* [[Diabetes mellitus]]

 
* [[Hyperuricaemia]]

 
|-

 
| '''[[Psychiatric]]'''

 
|

 
|

 
|

 
* [[Depression (mood)|Depression]]

 
* Aggravated depression

 
* Aggressive tendencies

 
* [[Anxiety]]

 
* Mood alterations

 
|

 
* Abnormal behaviour

 
* Psychotic disorder

 
* Suicidal ideation

 
* Suicide attempt

 
* Suicide

 
|-

 
| '''[[Nervous system]]'''

 
|

 
|

 
* Headache

 
|

 
|

 
* [[Benign intracranial hypertension]]

 
* [[Convulsions]]

 
* [[Drowsiness]]

 
* [[Dizziness]]

 
|-

 
| '''Eye'''

 
|

 
* [[Blepharitis]]

 
* [[Conjunctivitis]]

 
* [[Keratoconjunctivitis sicca|Dry eyes]]

 
* Eye irritation

 
|

 
|

 
|

 
* Blurred vision

 
* [[Cataract]]

 
* [[Colour blindness]]

 
* Contact lens intolerance

 
* Corneal opacity

 
* Decreased night vision

 
* [[Keratitis]]

 
* [[Papilloedema]]

 
* [[Photophobia]]

 
* Visual disturbances

 
|-

 
| '''Ear'''

 
|

 
|

 
|

 
|

 
* Impaired hearing

 
|-

 
| '''[[Vascular]]'''

 
|

 
|

 
|

 
|

 
* [[Vasculitis]] (i.e. [[Wegener's granulomatosis]],

 
allergic vasculitis)

 
|-

 
| '''Respiratory, [[thoracic]] and <br>

 
[[mediastinal]]'''

 
|

 
|

 
* [[Epistaxis]]

 
* Nasal dryness

 
* [[Nasopharyngitis]]

 
|

 
|

 
* [[Bronchospasm]] (particularly in patients

 
with asthma)

 
* [[Hoarseness]]

 
|-

 
| '''[[Gastrointestinal]]'''

 
|

 
|

 
|

 
|

 
* [[Colitis]]

 
* [[Ileitis]]

 
* Dry throat

 
* [[Gastrointestinal haemorrhage]]

 
* Haemorrhagic diarrhoea

 
* [[Inflammatory bowel disease]]

 
* [[Nausea]]

 
* [[Pancreatitis]]

 
|-

 
| '''[[Hepatobiliary]]'''

 
|

 
* Increased [[transaminase]]

 
|

 
|

 
|

 
* [[Hepatitis]]

 
|-

 
| '''Skin and<br> 

 
[[subcutaneous tissues]]'''

 
|

 
* [[Cheilitis]]

 
* [[Dermatitis]]

 
* [[Xeroderma|Dry skin]]

 
* Localised exfoliation

 
* [[Pruritus]]

 
* Rash

 
* [[Erythematous]]

 
* Skin fragility

 
|

 
|

 
* [[Alopecia]]

 
|

 
* [[Acne fulminans]]

 
* Aggravated acne (acne flare)

 
* [[Erythema]] (facial)

 
* [[Exanthema]]

 
* Hair disorders

 
* [[Hirsutism]]

 
* [[Nail dystrophy]]

 
* [[Paronychia]]

 
* [[Photosensitivity reaction]]

 
* [[Pyogenic granuloma]]

 
* Skin [[hyperpigmentation]]

 
* Increased sweating

 
|-

 
| '''[[Musculo-skeletal]] and<br> 

 
[[connective tissue]]'''

 
|

 
* [[Arthralgia]]

 
* [[Myalgia]]

 
* Back pain

 
|

 
|

 
|

 
* [[Arthritis]]

 
* [[Calcinosis]] (calcification of ligaments

 
and tendons)

 
* Premature epiphyseal fusion

 
* [[Exostosis]]

 
* [[Hyperostosis]]

 
* [[Osteopenia]]

 
* [[Tendonitis]]

 
|-

 
| '''[[Kidney]] and [[urinary]]'''

 
|

 
|

 
|

 
|

 
* [[Glomerulonephritis]]

 
|-

 
| '''General'''

 
|

 
|

 
|

 
|

 
* Increased formation of [[granulation tissue]]

 
* [[Malaise]]

 
|-

 
| '''Investigation'''

 
|

 
* Increased [[triglycerides]]

 
* Decreased [[High-density lipoprotein|HDL]]

 
|

 
* Increased blood cholesterol

 
* Increased blood glucose

 
* [[Haematuria]]

 
* [[Proteinuria]]

 
|

 
|

 
*  Increased  [[creatine phosphokinase]]

 
|-

 
|}

 


 
Isotretinoin may stop [[long bone]] growth in young people who are still growing.<ref name=USlabel2010>{{Cite report |origyear= January 2010 |title= US Label |url= http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018662s060lbl.pdf |format=PDF |publisher= FDA |date= 22 October 2010 |accessdate= 1 June 2017 }} See [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018662 FDA Index page for NDA 018662] for updates</ref> Several reports state that premature [[epiphyseal]] closure can occur in acne patients receiving recommended doses of Accutane.<ref>{{cite journal |vauthors=Lawson JP, McGuire J | title = The spectrum of skeletal changes associated with long-term administration of 13-cis-retinoic acid | journal = Skeletal Radiology | volume = 16 | issue = 2 | pages = 91–7 | year = 1987 | pmid = 3107131 | doi = 10.1007/BF00367754 }}</ref><ref>{{cite journal |vauthors=David M, Hodak E, Lowe NJ | title = Adverse effects of retinoids | journal = Medical toxicology and adverse drug experience | volume = 3 | issue = 4 | pages = 273–88 | year = 1988 | pmid = 3054426 | doi = 10.1007/bf03259940 }}</ref><ref>{{cite journal | author = Orfanos CE | title = Retinoide: der neue Stand. Erhaltungstherapie, Resorptionsstörungen bei 'non-responders', Interaktionen und Interferenzen mit Medikamenten, Behandlung von Kindern und Knochentoxizität, Acitretin und 13-cis-Acitretin | language = German | journal = Hautarzt | volume = 40 | issue = 3 | pages = 123–9 | year = 1989 | pmid = 2523875 | trans_title = Retinoids: the new status. Maintenance therapy, disorders of resorption in 'non-responders', interactions and interferences with drugs, treatment of children and bone toxicity, acitetin and 13-cis-acitretin }}</ref><ref>{{cite journal | author = DiGiovanna JJ | title = Isotretinoin effects on bone | journal = Journal of the American Academy of Dermatology | volume = 45 | issue = 5 | pages = S176–82 | year = 2001 | pmid = 11606950 | doi = 10.1067/mjd.2001.113721 }}</ref>

 


 
Isotretinoin is known to cause [[meibomian gland]] dysfunction which causes persistent [[keratoconjunctivitis sicca]] (dry eye).<ref name=Moy2015rev>{{cite journal | vauthors = Moy A, McNamara NA, Lin MC | title = Effects of Isotretinoin on Meibomian Glands | journal = Optometry and Vision Science | volume = 92 | issue = 9 | pages = 925–30 | date = September 2015 | pmid = 26154692 | doi = 10.1097/OPX.0000000000000656 }}</ref> It has also been found to cause [[salivary gland]] dysfunction in some people, causing xerostomia (dry mouth).<ref>{{cite journal | vauthors = Örsal E, Seven B, Erdem MT, Varoğlu E, Farimaz H, Ayan AK | title = Evaluation of the effect of isotretinoin on salivary gland function by Tc-99m pertechnetate imaging in acne vulgaris patients | journal = Turkish Journal of Medical Sciences | volume = 45 | issue = 3 | pages = 674–7 | pmid = 26281338 | doi = 10.3906/sag-1402-131 }}</ref><ref>{{cite journal | vauthors = Lupi-Pégurier L, Muller-Bolla M, Fontas E, Ortonne JP | title = Reduced salivary flow induced by systemic isotretinoin may lead to dental decay. A prospective clinical study | journal = Dermatology | volume = 214 | issue = 3 | pages = 221–6 | pmid = 17377383 | doi = 10.1159/000099586 }}</ref><ref>{{cite journal | vauthors = Oikarinen K, Salo T, Kylmäniemi M, Palatsi R, Karhunen T, Oikarinen A | title = Systemic oral isotretinoin therapy and flow rate, pH, and matrix metalloproteinase-9 activity of stimulated saliva | journal = Acta Odontologica Scandinavica | volume = 53 | issue = 6 | pages = 369–71 | date = December 1995 | pmid = 8849870 | doi = 10.3109/00016359509006003 }}</ref><ref>{{cite journal | vauthors = Reynolds NJ, Gough M, Clamp JR, Burton JL | title = Effect of oral isotretinoin therapy on saliva volume and composition | journal = The British Journal of Dermatology | volume = 125 | issue = 2 | pages = 189–90 | date = August 1991 | pmid = 1832930 | doi = 10.1111/j.1365-2133.1991.tb06071.x }}</ref> Problems with the meibomian and salivary glands are likely due to the [[Ligand (biochemistry)#Selective and non-selective|non-selective]] [[apoptosis]] of the cells of the [[exocrine gland]]s.<ref name="Lambert_1989" /> Decreased [[night vision]] has been reported to persist in some patients after discontinuation of isotretinoin therapy.<ref>{{cite journal | vauthors = Mollan SP, Woodcock M, Siddiqi R, Huntbach J, Good P, Scott RA | title = Does use of isotretinoin rule out a career in flying? | journal = The British Journal of Ophthalmology | volume = 90 | issue = 8 | pages = 957–9 | date = August 2006 | pmid = 16723361 | pmc = 1857209 | doi = 10.1136/bjo.2006.092833 }}</ref><ref name="autogenerated299">{{cite journal | vauthors = Fraunfelder FT, Fraunfelder FW, Edwards R | title = Ocular side effects possibly associated with isotretinoin usage | journal = American Journal of Ophthalmology | volume = 132 | issue = 3 | pages = 299–305 | date = September 2001 | pmid = 11530040 | doi = 10.1016/S0002-9394(01)01024-8 }}</ref>

 


 
[[Hyperostosis]] has been reported in patients receiving treatment with isotretinoin.<ref>{{cite journal |vauthors=Pittsley RA, Yoder FW | title = Retinoid Hyperostosis | journal = New England Journal of Medicine | volume = 308 | issue = 17 | pages = 1012–4 | year = 1983 | pmid = 6403861 | doi = 10.1056/NEJM198304283081707 }}</ref><ref>{{cite journal |vauthors=Tangrea JA, Kilcoyne RF, Taylor PR, Helsel WE, Adrianza ME, Hartman AM, Edwards BK, Peck GL | title = Skeletal hyperostosis in patients receiving chronic, very-low-dose isotretinoin | journal = Archives of dermatology | volume = 128 | issue = 7 | pages = 921–5 | year = 1992 | pmid = 1626958 | doi = 10.1001/archderm.1992.01680170053004 }}</ref>

 

